{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Total+Cholesterol&page=10",
    "query": {
      "intervention": "Total Cholesterol",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 653,
    "total_pages": 66,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Total+Cholesterol&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Total+Cholesterol&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-13T11:28:30.309Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01288469",
      "title": "Efficacy and Safety Evaluation of Alirocumab (SAR236553/REGN727) When Co-administered With High Dose of Atorvastatin in Patients With Primary Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for alirocumab)",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo (for atorvastatin)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 92,
      "start_date": "2011-01",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2015-09-24",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 20,
      "location_summary": "Mesa, Arizona • Tucson, Arizona • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Doral",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01288469"
    },
    {
      "nct_id": "NCT05918861",
      "title": "Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome"
      ],
      "interventions": [
        {
          "name": "Dalcetrapib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "DalCor Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "45 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "45 Years and older"
      },
      "enrollment_count": 2000,
      "start_date": "2023-10-03",
      "completion_date": "2027-08",
      "has_results": false,
      "last_update_posted_date": "2026-06-22",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 186,
      "location_summary": "Alexander City, Alabama • Birmingham, Alabama • Fairhope, Alabama + 163 more",
      "locations": [
        {
          "city": "Alexander City",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Fairhope",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05918861"
    },
    {
      "nct_id": "NCT00529542",
      "title": "A Trial of Lipitor (Atorvastatin) for the Treatment of Polycystic Ovary Syndrome (PCOS) in Women With Elevated Low-density Lipoprotein (LDL) Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polycystic Ovary Syndrome"
      ],
      "interventions": [
        {
          "name": "Lipitor",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Milton S. Hershey Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "40 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 40 Years · Female only"
      },
      "enrollment_count": 20,
      "start_date": "2004-12",
      "completion_date": "2010-08",
      "has_results": true,
      "last_update_posted_date": "2014-09-25",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 1,
      "location_summary": "Hershey, Pennsylvania",
      "locations": [
        {
          "city": "Hershey",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00529542"
    },
    {
      "nct_id": "NCT02585895",
      "title": "Evolocumab Compared to LDL-C Apheresis in Patients Receiving LDL-C Apheresis Prior to Study Enrollment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Low-density Lipoprotein Cholesterol (LDL-C) Apheresis",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 39,
      "start_date": "2015-12-21",
      "completion_date": "2017-01-20",
      "has_results": true,
      "last_update_posted_date": "2022-11-30",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 4,
      "location_summary": "Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Grandville",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02585895"
    },
    {
      "nct_id": "NCT05641753",
      "title": "Cholesterol Lowering and Residual Risk in Diabetes, Type 1",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Evolocumab Cartridge",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin Calcium Tablets",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe Tablets",
          "type": "DRUG"
        },
        {
          "name": "18F-FDG",
          "type": "DRUG"
        },
        {
          "name": "Angiocatheter 20IV",
          "type": "DEVICE"
        },
        {
          "name": "J-Wire",
          "type": "DEVICE"
        },
        {
          "name": "GlycoCheck Glycocalyx Measurement Software",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "NYU Langone Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 125,
      "start_date": "2022-12-06",
      "completion_date": "2027-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-10-28",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 4,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05641753"
    },
    {
      "nct_id": "NCT00006071",
      "title": "Effects of Rosiglitazone on Blood Vessels in Patients With High Blood Pressure and High Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hypercholesterolemia",
        "Hypertension"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 120,
      "start_date": "2000-07",
      "completion_date": "2001-03",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00006071"
    },
    {
      "nct_id": "NCT00239681",
      "title": "JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Elevated High-sensitivity C-Reactive Protein (hsCRP)"
      ],
      "interventions": [
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 17802,
      "start_date": "2003-02",
      "completion_date": "2008-09",
      "has_results": true,
      "last_update_posted_date": "2014-03-24",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 431,
      "location_summary": "Birmingham, Alabama • Calera, Alabama • Columbiana, Alabama + 428 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Calera",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Decatur",
          "state": "Alabama"
        },
        {
          "city": "Graysville",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00239681"
    },
    {
      "nct_id": "NCT00831129",
      "title": "A Study for Pre-diabetic Patients With Cholesterol Lowering Drugs",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Pre-diabetes"
      ],
      "interventions": [
        {
          "name": "Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Placebo Rosiglitazone",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "21 Years to 75 Years"
      },
      "enrollment_count": 53,
      "start_date": "2006-09",
      "completion_date": "2011-04",
      "has_results": true,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00831129"
    },
    {
      "nct_id": "NCT02833844",
      "title": "Safety, Tolerability and Efficacy on Low Density Lipoprotein Cholesterol (LDL-C) of Evolocumab in Participants With Human Immunodeficiency Virus (HIV) and Hyperlipidemia/Mixed Dyslipidemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Subjects With Hyperlipidemia, Dyslipidemia and HIV Infection"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 467,
      "start_date": "2017-05-22",
      "completion_date": "2020-01-27",
      "has_results": true,
      "last_update_posted_date": "2022-07-22",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 20,
      "location_summary": "Los Angeles, California • Hartford, Connecticut • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Hartford",
          "state": "Connecticut"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833844"
    },
    {
      "nct_id": "NCT05238519",
      "title": "Improved Diagnosis of Familial Hypercholesterolemia Across the Northland (ID-FH)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Familial Hypercholesterolemia",
        "Cholesterol, Elevated",
        "Genetic Disease"
      ],
      "interventions": [
        {
          "name": "Motivational interview (MI)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Essentia Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 257,
      "start_date": "2022-02-15",
      "completion_date": "2025-08-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-04",
      "last_synced_at": "2026-11-13T11:28:30.309Z",
      "location_count": 2,
      "location_summary": "Duluth, Minnesota",
      "locations": [
        {
          "city": "Duluth",
          "state": "Minnesota"
        },
        {
          "city": "Duluth",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05238519"
    }
  ]
}